Skip to main content

The prognosis and management of neuroendocrine neoplasms-related metastatic bone disease: lessons from clinical practice

Endocrine volume 64, pages 690–701 (2019)Cite this article

Abstract

Purpose

To study the evolution and optimal management of metastatic bone disease (mBD) in patients with neuroendocrine neoplasms (NENs).

Methods

Seventy-four patients were recruited from four NEN centers in this observational multicenter study.

Results

Pancreas and small bowel were the most common primaries (30 and 27%, respectively). Almost all gastrointestinal (GI)-NENs were grades 1 and 2, whereas bronchopulmonary-thymic were atypical carcinoids. Thirty-two (43%) patients had synchronous metastatic bone disease (mBD) and three patients reported bone-specific symptoms; metachronous mBD developed at a median of 35 (range: 4–395) months. Thirty-six (86%) of patients with metachronous mBD had stage IV disease at diagnosis. Somatostatin receptor functional imaging and computed tomography were the modalities mostly used for mBD identification. Fifty-two patients received assessable bone-related therapy (bisphosphonates, denosumab, local radiotherapy, and radionuclide treatment). Improvement in mBD was seen in 5, stable disease in 22, and deterioration in 25 patients. The presence of synchronous mBD and the negative outcome of bone-related therapy negatively affected overall survival (OS). In the multivariate analysis, the stronger predictor of OS was the outcome of bone-related therapy (HR: 4.753; 95% CI: 1.589–14.213). Bisphosphonates therapy was the mostly used bone-specific treatment but its monthly administration did not affect OS. At last follow-up, 39 patients were alive with OS 50 (14–463) months.

Conclusions

Early investigation for mBD offers a prognostic marker of patients with NENs, since synchronous mBD has a negative impact on survival. The outcome of bone-related therapy affects OS but the monthly administration of bisphosphonates did not show a benefit over less intense schemes.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. W.G. Meijer, E. van der Veer, P.L. Jager, E.J. van der Jagt, B.A. Piers, I.P. Kema, E.G. de Vries, P.H. Willemse, Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. J. Nucl. Med. 44, 184–191 (2003)

    PubMed  Google Scholar 

  2. R. Hlatky, D. Suki, R. Sawaya, Carcinoid metastasis to the brain. Cancer 101, 2605–2613 (2004)

    Article  PubMed  Google Scholar 

  3. C. Lombard-Bohas, E. Mitry, D. O’Toole, C. Louvet, D. Pillon, G. Cadiot, F. Borson-Chazot, T. Aparicio, M. Ducreux, T. Lecomte, P.L. Etienne, W. Cacheux, J.L. Legoux, J.F. Seitz, P. Ruszniewski, J.A. Chayvialle, P. Rougier, FFCD-ANGH-GERCOR, Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France. Neuroendocrinology 89, 217–222 (2009).

    Article  CAS  PubMed  Google Scholar 

  4. J. Keiser, E.K. Nakakura, L. Imhoff, M.A. Mayorga, S. Bobiak, A.P. Venook, E.K. Bergsland, Incidence and natural history of bone metastases in neuroendocrine tumors [Abstract]. J. Clin. Oncol. 30(Suppl 4), 340 (2012)

    Article  Google Scholar 

  5. E.T. Janson, L. Holmberg, M. Stridsberg, B. Eriksson, E. Theodorsson, E. Wilander, K. Oberg, Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann. Oncol. 8, 685–690 (1997)

    Article  CAS  PubMed  Google Scholar 

  6. E.M. Ross, W.C. Roberts, The carcinoid syndrome: comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease. Am. J. Med. 79, 339–354 (1985)

    Article  CAS  PubMed  Google Scholar 

  7. J.M. Zuetenhorst, C.A. Hoefnageli, H. Boot, R.A. Valdés Olmos, B.G. Taal, Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl. Med. Commun. 23, 735–741 (2002)

    Article  CAS  PubMed  Google Scholar 

  8. J.M. Zuetenhorst, B.G. Taal, Metastatic carcinoid tumors: a clinical review. Oncologist 10, 123–131 (2005)

    Article  PubMed  Google Scholar 

  9. F. Macedo, K. Ladeira, F. Pinho, N. Saraiva, N. Bonito, L. Pinto, F. Goncalves, Bone metastases: an overview. Oncol. Rev. 11, 321 (2017)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. M. Gnant, P. Clézardin, Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treat. Rev. 38, 407–415 (2012)

    Article  CAS  PubMed  Google Scholar 

  11. L.S. Rosen, D. Gordon, N.S. Tchekmedyian, R. Yanagihara, V. Hirsh, M. Krzakowski, M. Pawlicki, P. De Souza, M. Zheng, G. Urbanowitz, D. Reitsma, J. Seaman, Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100, 2613–2621 (2004)

    Article  CAS  PubMed  Google Scholar 

  12. S. Sousa, P. Clézardin, Bone-targeted therapies in cancer-induced bone disease. Calcif. Tissue Int. 102, 227–250 (2018)

    Article  CAS  PubMed  Google Scholar 

  13. K. Alexandraki, A. Angelousi, G. Boutzios, G. Kyriakopoulos, D. Rontogianni, G. Kaltsas, Management of neuroendocrine tumors of unknown primary. Rev. Endocr. Metab. Disord. 18, 423–431 (2017)

    Article  CAS  PubMed  Google Scholar 

  14. K. Van Loon, L. Zhang, J. Keiser, C. Carrasco, K. Glass, M.T. Ramirez, S. Bobiak, E.K. Nakakura, A.P. Venook, M.H. Shah, E.K. Bergsland, Bone metastases and skeletal-related events from neuroendocrine tumors. Endocr. Connect. 4, 9–17 (2015)

    Article  PubMed  PubMed Central  Google Scholar 

  15. M. Scharf, V. Petry, H. Daniel, A. Rinke, T.M. Gress, Bone metastases in patients with neuroendocrine neoplasm: frequency and clinical, therapeutic, and prognostic relevance. Neuroendocrinology 106, 30–37 (2018)

    Article  CAS  PubMed  Google Scholar 

  16. D.H. Nguyen, P.T. Truong, C.V. Walter, E. Hayashi, J.L. Christie, C. Alexander, Limited M1 disease: a significant prognostic factor for stage IV breast cancer. Ann. Surg. Oncol. 19, 3028–3034 (2012)

    Article  PubMed  Google Scholar 

  17. P. Soyer, A. Roche, D. Elias, M. Levesque, Hepatic metastases from colorectal cancer: influence of hepatic volumetric analysis on surgical decision making. Radiology 184, 695–697 (1992)

    Article  CAS  PubMed  Google Scholar 

  18. A. Perren, A. Couvelard, J.Y. Scoazec, F. Costa, I. Borbath, G. Delle Fave, V. Gorbounova, D. Gross, A. Grossman, R.T. Jense, M. Kulke, K. Oeberg, G. Rindi, H. Sorbye, S. Welin; Antibes Consensus Conference participants, ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification. Neuroendocrinology 105, 196–200 (2017)

  19. F. Panzuto, S. Nasoni, M. Falconi, V.D. Corleto, G. Capurso, S. Cassetta, M. Di Fonzo, V. Tornatore, M. Milione, S. Angeletti, M.S. Cattaruzza, V. Ziparo, C. Bordi, P. Pederzoli, G. Delle Fave, Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr. Relat. Cancer 12, 1083–1092 (2005)

    Article  PubMed  Google Scholar 

  20. B. Kos-Kudła, D. O’Toole, M. Falconi, D. Gross, G. Klöppel, A. Sundin, J. Ramage, K. Oberg, B. Wiedenmann, P. Komminoth, E. Van Custem, M. Mallath, M. Papotti, M. Caplin; Palma de Mallorca Consensus Conference Participants, ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors. Neuroendocrinology 91, 341–350 (2010)

    Article  CAS  PubMed  Google Scholar 

  21. G. Kaltsas, A. Rockall, D. Papadogias, R. Reznek, A.B. Grossman., Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur. J. Endocrinol. 151, 15–27 (2004)

    Article  CAS  PubMed  Google Scholar 

  22. U. Knigge, J. Capdevila, D.K. Bartsch, E. Baudin, J. Falkerby, R. Kianmanesh, B. Kos-Kudla, B. Niederle, E. Nieveen van Dijkum, D. O’Toole, A. Pascher, N. Reed, A. Sundin, M.P. Vullierme; Antibes Consensus Conference Participants; Antibes Consensus Conference participants, ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: follow-up and documentation. Neuroendocrinology 105, 310–319 (2017)

    Article  CAS  PubMed  Google Scholar 

  23. D. Putzer, M. Gabriel, B. Henninger, D. Kendler, C. Uprimny, G. Dobrozemsky, C. Decristoforo, R.J. Bale, W. Jaschke, I.J. Virgolini, Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J. Nucl. Med. 50, 1214–1221 (2009)

    Article  PubMed  Google Scholar 

  24. H.J. Hansmann, C. Wunsch, B. Schneider, M. Brado, M. Flesch, G.M. Richter, G.W. Kauffmann, Radiologic diagnosis of bone metastases. Orthopade 27, 224–230 (1998)

    CAS  PubMed  Google Scholar 

  25. J. Kavecansky, L. Wei, L. Caronia, M.T. Ramirez, M. Bloomston, M.H. Shah, Bone metastases in well-to-moderately differentiated neuroendocrine tumors: a single institutional review from the Ohio State University Medical Center. Pancreas 44, 198–203 (2015)

    Article  CAS  PubMed  Google Scholar 

  26. F. Gibril, J.L. Doppman, J.C. Reynolds, C.C. Chen, V.E. Sutliff, F. Yu, J. Serrano, D.J. Venzon, R.T. Jensen, Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management. J. Clin. Oncol. 16, 1040–1053 (1998)

    Article  CAS  PubMed  Google Scholar 

  27. R. Lebtahi, G. Cadiot, N. Delahaye, R. Genin, D. Daou, M.C. Peker, D. Chosidow, M. Faraggi, M. Mignon, D. Le Guludec, Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy. J. Nucl. Med. 40, 1602–1608 (1999)

    CAS  PubMed  Google Scholar 

  28. M. Raderer, A. Kurtaran, M. Leimer, P. Angelberger, B. Niederle, H. Vierhapper, F. Vorbeck, M.H. Hejna, W. Scheithauer, J. Pidlich, I. Virgolini, Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998. J. Clin. Oncol. 18, 1331–1336 (2000)

    Article  CAS  PubMed  Google Scholar 

  29. D.J. Kwekkeboom, J.J. Teunissen, W.H. Bakker, P.P. Kooij, W.W. de Herder, R.A. Feelders, C.H. van Eijck, J.P. Esser, B.L. Kam, E.P. Krenning., Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J. Clin. Oncol. 23, 2754–2762 (2005)

    Article  CAS  PubMed  Google Scholar 

  30. A. Sabet, F. Khalaf, T. Haslerud, A. Al-Zreiqat, A. Sabet, B. Simon, T.D. Pöppel, H.J. Biersack, S. Ezziddin, Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis. Am. J. Nucl. Med. Mol. Imaging 3, 437–445 (2013)

    PubMed  PubMed Central  Google Scholar 

  31. S. Ezziddin, A. Sabet, F. Heinemann, C.J. Yong-Hing, H. Ahmadzadehfar, S. Guhlke, T. Höller, W. Willinek, C. Boy, H.J. Biersack, Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate. J. Nucl. Med. 52, 1197–1203 (2011)

    Article  PubMed  Google Scholar 

  32. M. Gnant, J. Baselga, H.S. Rugo, S. Noguchi, H.A. Burris, M. Piccart, G.N. Hortobagyi, J. Eakle, H. Mukai, H. Iwata, M. Geberth, L.L. Hart, P. Hadji, M. El-Hashimy, S. Rao, T. Taran, T. Sahmoud, D. Lebwohl, M. Campone, K.I. Pritchard, Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. J. Natl. Cancer Inst. 105, 654–663 (2013)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

  1. Endocrine Unit, 1st Department of Propaedeutic Medicine, Laiko University Hospital, Medical School, National and Kapodistrian University of Athens, Mikras Asias 75, Athens, 11527, Greece

    Krystallenia I. Alexandraki, Dimitrios Thomas, Denise Kolomodi, Marina Tsoli & Gregory Kaltsas

  2. Institute of Liver Studies, King’s College Hospital, London, SE5 9RS, UK

    Michail Pizanias & Rajaventhan Srirajaskanthan

  3. Neuroendocrine Tumor Unit, Endocrinology and Metabolism Department, Division of Medicine, Hadassah-Hebrew University Medical Center, P.O.B. 12000, 91120, Jerusalem, Israel

    Inbal Uri, David J. Gross & Simona Grozinsky-Glasberg

  4. The ARDEN NET Centre, University Hospitals Coventry & Warwickshire NHS Trust, Coventry, UK

    Tristan Page, Chen Sheng Low, Olu Adesanya, Harpal Randeva, Gregory Kaltsas & Martin O. Weickert

  5. Coventry University, Centre for Applied Biological & Exercise Science, Coventry, UK

    Harpal Randeva & Martin O. Weickert

  6. Clinical Sciences Research Laboratories, Division of Translational Medicine, Warwick Medical School, University Hospital, University of Warwick, CV4 7AL, Coventry, UK

    Harpal Randeva & Martin O. Weickert

Authors
  1. Krystallenia I. Alexandraki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michail Pizanias
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Inbal Uri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dimitrios Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tristan Page
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Denise Kolomodi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chen Sheng Low
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Olu Adesanya
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Marina Tsoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. David J. Gross
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Harpal Randeva
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Rajaventhan Srirajaskanthan
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Simona Grozinsky-Glasberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Gregory Kaltsas
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Martin O. Weickert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Krystallenia I. Alexandraki.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Formal consent was given by all participants.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors should be considered as senior authors: Gregory Kaltsas, Martin O. Weickert

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Alexandraki, K.I., Pizanias, M., Uri, I. et al. The prognosis and management of neuroendocrine neoplasms-related metastatic bone disease: lessons from clinical practice. Endocrine 64, 690–701 (2019). https://doi.org/10.1007/s12020-019-01838-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-019-01838-8

Keywords

  • Neuroendocrine neoplasms
  • Metastatic bone disease
  • Bisphosphonates
  • Denosumab